Every day researchers work towards finding new breakthroughs in cancer. Clinical trials play a pivotal role in bringing that defeat closer.
Clinical trials test promising new treatments on people to see if they are better than existing cancer treatments. The trial process is long starting many years before an actual treatment can be used.
By joining a clinical trial you are helping to create new breakthroughs in cancer research. Hundreds of thousands of people all over the world have taken part in clinical trials that have lead to safer and more effective treatments for many cancers.
It is important to note that not all cancer patients are eligible to take part in clinical trials and there are not clinical trials for all types of cancer.
You may decide to join a clinical trial because:
- The treatment you receive will be at least the best available for your illness.
- Your health may improve because of the treatment you receive.
- You may receive a treatment you would not otherwise have access to.
- Your health will be carefully checked by the treatment team running the trial.
- You will be part of the worldwide effort to improve cancer treatment.
For more information on clinical trials please click here.
If you would like information regarding any of the below clinical trials, please contact the appropriate Clinical trials manager:
Ashford Cancer Centre: Helen Daykin, +61 8 8292 2240
Flinders Medical Centre: Alex Scott-Hoy, +61 8 8204 4830
The Queen Elizabeth: Sue Yeend, +61 8 8222 6148
Lyell McEwin Hospitals: Julie Rowe or Rohit Joshi +61 8 8282 0833
Royal Adelaide Hospital: Anne Milton, +61 8 7074 2342
Current clinical trials for bowel & colon cancer
|Not Yet Recruiting||ACES Feasibility study of adjuvant chemotherapy in patients with oesophageal cancer who received neoadjuvant chemotherapy and underwent curative surgery||Flinders Medical Centre|
|Recruiting||AG1013GST A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)||Ashford Cancer Centre Research|
|Recruiting||ALT GIST - A randomised phase II trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (GIST)||Flinders Medical Centre|
|Recruiting||ASCOLT - Aspirin for Dukes C and high risk Dukes B colorectal cancers||The Lyell McEwin Hospital|
|Recruiting||BNC101.001A Phase I, Dose Escalation Study of BNC101 (anti-LGR5 humanized monoclonal antibody) in patients with metastatic colorectal cancer||Flinders Medical Centre|
|Recruiting||CA209-649 - A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab versus Oxaliplatin plus Fluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer||Royal Adelaide Hospital|
|Recruiting||CanStem303C - A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) with or without Bevacizumab in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC).||The Queen Elizabeth Hospital|
|Recruiting||cfDNA-06 Evaluation of temporal dynamics of RAS Mutation Emergence in Cell Free DNA (cfDNA) in response to first-line cetuximab anti-EGFR therapy in Patients with Metastatic Colorectal Cancer||The Queen Elizabeth Hospital|
|Recruiting||A Phase III study of the impact of a physical activity program on disease-free survival in patients with high risk stage II or stage III colon cancer: a randomised controlled trial (CHALLENGE)||Flinders Medical Centre|
|Recruiting||Challenge - A study of colon health and life long exercise change||The Queen Elizabeth Hospital|
|Recruiting||Challenge - colon health and life long exercise change. This study is a phase 3 RCT for people with stage 2 or 3 colon cancer who have completed adjuvant chemotherapy 2-6 months ago||Royal Adelaide Hospital|
|Not yet recruiting||Control nets - Capecitabine ON Temozolomide Radionuclide therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study||The Queen Elizabeth Hospital|
|Not Yet Recruiting||DYNAMIC - Circulating Tumour DNA analysis informing adjuvant chemotherapy in Stage II Colon Cancer||Flinders Medical Centre|
|Not yet Recruiting||INTEGRATE 2 A Randomised Phase III Double-Blind Placebo- controlled Study of regorafenib in Refractrory Advanced Gastro-Oesophageal Cancer (AGOC)||Flinders Medical Centre|
|Not yet Recruiting||INTEGRATE II A Randomised Phase III Double‐Blind Placebo‐Controlled Study of regorafenib in Refractory Advanced Gastro‐Oesophageal Cancer (AGOC)||The Queen Elizabeth Hospital|
|Recruiting||IPGP - Phase I open label trial of Intraperitoneal Paclitaxel in combination with intravenous cisplatin and oral capecitabine in patients with advanced Gastric cancer and Peritoneal metastases||Flinders Medical Centre|
|Recruiting||Javelin 100 A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction||Lyell McEwin Hospital|
|Recruiting||Javelin Gastric 100 A Phase III open-label, multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first- line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction||Flinders Medical Centre|
|Recruiting||KEYNOTE-177 A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)||The Queen Elizabeth Hospital|
|Not yet recruiting||NABNEC A randomised Phase 2 study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas.||Flinders Medical Centre|
|Not yet recruiting||Reno Pro Study of Patient Reported Outcomes in Rectal Cancer Survivors who had complete clinical response with Chemoradiation and then were followed by Wait and Watch strategy||Flinders Medical Centre|
|Recruiting||SAUL - An Open Label, Single Arm, Multicenter, Safety Study Of Atezolizum Locally Advanced Or Metastatic Urothelial Or Non-Urothelial Carcinoma Of The Urinary Tract. Protocol: Saul Mo29983||Royal Adelaide Hospital|
|Recruiting||Top Gear - Trial of preoperative therapy for gastric and esophagogastric junction adenocarcinoma: A randomised phase 2/3 trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer||Flinders Medical Centre|